NIKKEI 225
39,173.15 +368.50 (+0.95%) HANG SENG
18,085.31 +57.60 (+0.32%) CRUDE OIL
81.67 +0.04 (+0.05%) GOLD FUTURES
2,335.50 -8.90 (-0.38%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,095.58 -987.84 (-2.01%)
ARCT Jul 2024 30.000 call
| Previous close | 1.3500 |
| Open | 1.3500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 30.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.2400 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireArcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
SAN DIEGO, June 20, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors.
GuruFocus.comInsider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)
On June 12, 2024, Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), executed a significant transaction by selling 50,000 shares of the company.
Business WireArcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
SAN DIEGO, June 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in G
